Genetic Technologies Limited (GENE) Income Statement
GENE FY2024 at a glance
Fiscal year ended June 30, 2024 · Australian dollarsGENE revenue and net income
Where GENE's revenue goes
FY2024Each bar shows an amount and its share of revenue. GENE kept −156.8% of revenue as net income.
GENE profit margins
GENE growth rates
to FY2024| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −25.9% | +299.1% | +213.2% | +5.3% |
| Gross profit | −35.1% | — | — | +9.0% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
GENE income statement in Australian dollars
| FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | A$7.7M | A$10.3M | A$6.8M | A$120,554 | A$9,864 | A$25,444 | A$189,254 | A$518,506 | A$824,586 | A$2.0M |
| Cost of revenue | A$3.8M | A$4.3M | A$321,223 | A$361,027 | A$251,511 | A$276,267 | A$300,088 | A$492,417 | A$743,060 | A$1.3M |
| Gross profit | A$3.9M | A$6.0M | A$6.5M | −A$240,473 | −A$241,647 | −A$250,823 | −A$110,834 | A$26,089 | A$81,526 | A$685,257 |
| Research & development | A$752,754 | A$1.3M | A$705,507 | A$3.1M | A$2.5M | A$2.4M | A$2.2M | A$2.4M | A$2.7M | A$2.9M |
| Sales, general & admin | A$12.8M | A$10.8M | A$2.2M | A$4.2M | A$4.1M | A$3.8M | A$3.0M | A$5.8M | A$3.0M | A$4.2M |
| Total operating expenses | A$16.1M | A$18.1M | A$3.1M | A$7.0M | A$6.0M | A$5.9M | A$5.3M | A$8.4M | A$8.6M | A$9.3M |
| Operating income | −A$12.2M | −A$10.4M | −A$7.5M | −A$7.1M | −A$6.1M | −A$6.0M | −A$6.4M | −A$8.2M | −A$8.5M | −A$9.9M |
| Interest income | A$119,511 | A$220,161 | A$36,256 | A$62,394 | A$22,507 | A$25,794 | A$15,218 | A$38,765 | A$67,100 | — |
| Interest expense | A$51,622 | A$29,515 | A$15,215 | A$14,049 | A$14,823 | A$20,031 | A$28,843 | A$31,995 | A$28,889 | A$264,694 |
| Income before taxes | −A$12.0M | −A$11.9M | −A$7.2M | −A$7.1M | −A$6.1M | −A$6.4M | −A$5.5M | −A$8.4M | −A$8.5M | −A$8.8M |
| Income taxes | −A$2.0M | −A$158,329 | −A$32,125 | A$130,320 | A$205,146 | A$407,482 | −A$299,351 | −A$253,159 | −A$359,803 | A$597,312 |
| Net income | −A$12.0M | −A$11.8M | −A$7.1M | −A$7.2M | −A$6.3M | −A$6.8M | −A$5.5M | −A$8.4M | −A$8.5M | −A$8.8M |
| EBITDA | −A$11.4M | −A$11.2M | −A$7.2M | −A$7.1M | −A$6.1M | −A$6.0M | −A$5.5M | −A$7.8M | −A$8.1M | −A$8.4M |
| Gross margin | 50.9% | 58.1% | 95.3% | −199.5% | −2,449.8% | −985.8% | −58.6% | 5.0% | 9.9% | 34.1% |
| Operating margin | −159.3% | −100.7% | −111.0% | −5,859.3% | −61,679.9% | −23,573.7% | −3,383.6% | −1,575.9% | −1,030.2% | −490.4% |
| Net margin | −156.8% | −113.6% | −104.9% | −5,979.0% | −63,909.9% | −26,855.4% | −2,887.1% | −1,620.8% | −1,025.8% | −437.9% |
| Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | Dec '22 | Sep '22 | Jun '22 | Mar '22 | Dec '21 | Sep '21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | A$4.8M | A$2.4M | A$4.0M | A$2.4M | A$4.5M | A$2.7M | A$4.2M | A$2.5M | A$5.8M | A$2.9M | A$3.5M | A$1.7M |
| Cost of revenue | A$2.0M | A$1.0M | A$5.9M | A$878,216 | A$5.8M | A$1.1M | A$5.7M | A$1.1M | A$1.9M | A$942,327 | A$1.1M | A$564,440 |
| Gross profit | A$2.8M | A$1.4M | −A$2.0M | A$1.6M | −A$1.2M | A$1.6M | −A$1.5M | A$1.4M | A$3.9M | A$1.9M | A$2.3M | A$1.2M |
| Research & development | A$362,996 | A$181,498 | A$389,758 | A$194,879 | A$722,851 | A$361,426 | A$558,306 | A$279,153 | A$334,546 | A$167,273 | A$370,961 | A$185,481 |
| Sales, general & admin | A$5.9M | A$1.1M | A$2.5M | A$995,458 | A$2.4M | A$933,608 | A$2.5M | A$1.2M | A$5.7M | A$1.1M | A$4.6M | A$816,027 |
| Total operating expenses | A$6.3M | A$3.1M | A$3.2M | A$4.8M | A$3.4M | A$4.8M | A$3.8M | A$4.3M | A$6.0M | A$3.6M | A$5.0M | A$3.1M |
| Operating income | −A$3.5M | −A$1.7M | −A$5.2M | −A$2.6M | −A$4.6M | −A$2.5M | −A$5.4M | −A$2.7M | −A$2.2M | −A$1.8M | −A$2.7M | −A$1.9M |
| Interest expense | A$38,769 | — | A$12,853 | — | A$13,643 | — | A$15,872 | — | — | — | A$11,696 | — |
| Income before taxes | −A$5.6M | −A$2.8M | −A$6.4M | −A$3.2M | −A$6.3M | −A$3.2M | −A$5.6M | −A$2.8M | −A$3.3M | −A$1.6M | −A$3.9M | −A$1.9M |
| Income taxes | −A$2 | −A$980,338 | −A$5 | — | −A$10,316 | A$5,158 | −A$148,013 | A$74,007 | −A$32,125 | A$16,063 | −A$1.2M | — |
| Net income | −A$5.6M | −A$2.8M | −A$6.4M | −A$3.2M | −A$6.3M | −A$3.1M | −A$5.5M | −A$2.7M | −A$3.2M | −A$1.6M | −A$3.9M | −A$1.9M |
| EBITDA | −A$5.3M | −A$2.6M | −A$4.9M | −A$2.4M | −A$4.7M | −A$2.5M | −A$5.1M | −A$2.5M | −A$3.3M | −A$1.8M | −A$3.7M | −A$1.8M |
| Gross margin | 58.3% | 58.3% | −50.0% | 64.0% | −27.0% | 59.3% | −37.2% | 56.9% | 67.3% | 67.3% | 67.3% | 67.3% |
| Operating margin | −72.3% | −72.3% | −130.4% | −106.0% | −101.1% | −93.6% | −129.8% | −108.3% | −37.5% | −63.4% | −76.8% | −112.7% |
| Net margin | −116.6% | −116.6% | −162.2% | −131.7% | −138.8% | −117.1% | −131.4% | −109.7% | −56.4% | −56.4% | −112.3% | −112.3% |
Quarterly columns are labeled by the month the quarter ended. Figures in Australian dollars as reported in GENE's financial statements (latest annual report filed June 30, 2024); data from EODHD. Sales, general & administrative expenses include sales and marketing.
GENE financial results
In fiscal year 2024 (ended June 30, 2024), Genetic Technologies reported revenue of A$7.7 million, down 25.9% from the year before. It had a net loss of A$12.0 million, a net profit margin of −156.8%. Over five years revenue grew at an average rate of 213.2% a year. Figures are in Australian dollars, the currency of its financial statements.
See the GENE stock overview for the latest quote and news, or the GENE chart for price history and technical indicators.
GENE income statement FAQ
What is Genetic Technologies's annual revenue?
Genetic Technologies reported total revenue of A$7.7 million for fiscal year 2024, which ended on June 30, 2024. That was down 25.9% from A$10.3 million the previous year.
Is Genetic Technologies profitable?
No. Genetic Technologies reported a net loss of A$12.0 million in fiscal 2024, a net profit margin of −156.8%; its operating margin was −159.3%.
What is Genetic Technologies's gross margin?
Genetic Technologies's gross margin was 50.9% in fiscal 2024: for every $100 of revenue, Genetic Technologies kept $51 after the direct cost of its products and services.
How much does Genetic Technologies spend on research and development?
Genetic Technologies spent A$0.8 million on research and development in fiscal 2024, 9.8% of revenue.
How fast is Genetic Technologies growing?
Revenue grew 213.2% a year on average over the last five fiscal years, from A$0.0 million to A$7.7 million.
When does Genetic Technologies's fiscal year end?
Genetic Technologies's fiscal year ends in June. The latest annual report covers the year ended June 30, 2024 and was filed on June 30, 2024.